ZVRA — Zevra Therapeutics, Inc. Stock Price, Chart & AI Report

Neutral Oct 6, 2025 • 21:51 UTC GlobeNewswire Inc. • Nichol Ochsner

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics announced granting options to purchase 38,000 shares of common stock to two new employees under its 2023 Employment Inducement Award Plan, with options vesting over four years.

ZVRA stock options employee compensation rare disease therapy

Sentiment note

Standard corporate action of granting employee stock options, indicating normal business operations without significant positive or negative implications

Positive Feb 27, 2025 • 12:30 UTC Benzinga • Globe Newswire

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, strengthening its balance sheet and supporting its strategic priorities.

ZVRA Zevra Therapeutics Rare Pediatric Disease Priority Review Voucher MIPLYFFA OLPRUVA

Sentiment note

The company has entered into a lucrative agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, which will strengthen its balance sheet and support its strategic priorities, including the commercial launches of its products MIPLYFFA and OLPRUVA.

Positive Dec 6, 2024 • 22:00 UTC GlobeNewswire Inc. • N/A

Zevra Therapeutics Announces Organizational Changes

Zevra Therapeutics is consolidating its development and scientific functions under the Chief Medical Officer, resulting in the departure of the Chief Development Officer and Chief Scientific Officer. The company is also discontinuing its in-house drug discovery activities and closing its laboratory facilities to focus on late-stage clinical development and commercial opportunities.

ZVRA Zevra Therapeutics organizational changes rare disease clinical development commercial opportunities

Sentiment note

The article highlights Zevra's strategic plan to focus on late-stage clinical and commercial opportunities, which is expected to position the company for continued success in the rare disease therapeutics market.

Positive Nov 21, 2024 • 21:51 UTC GlobeNewswire Inc. • N/A

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics announced the commercial availability of MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C. The company's comprehensive patient support program, AmplifyAssist, is in place to address access barriers.

ZVRA Zevra Therapeutics MIPLYFFA Niemann-Pick Disease Type C FDA approval patient support program

Sentiment note

The article highlights the commercial availability of Zevra's first FDA-approved treatment for a rare disease, which is a significant milestone for the company.

Positive Nov 11, 2024 • 21:36 UTC GlobeNewswire Inc. • Zevra Therapeutics, Inc.

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Zevra Therapeutics will present data at the 53rd Child Neurology Society Annual Meeting, demonstrating the relevance of the swallow domain in the Niemann-Pick disease Type C Clinical Severity Scale (NPCCSS). The study indicates that the NPCCSS swallow score reflects the patient's level of dysfunction, and a change in score reflects actual improvement or worsening in a patient's swallowing function.

ZVRA Niemann-Pick disease Type C NPCCSS swallow domain clinical severity scale arimoclomol

Sentiment note

The article highlights Zevra Therapeutics' efforts to demonstrate the relevance of the swallow domain in the NPCCSS, which is a key component of evaluating the effectiveness of their drug arimoclomol (MIPLYFFA) in the treatment of Niemann-Pick disease Type C. The positive sentiment is based on the company's proactive approach to improving the assessment of disease severity and treatment efficacy.

Positive Aug 2, 2024 • 21:50 UTC GlobeNewswire Inc. • Zevra Therapeutics, Inc.

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

The FDA Genetic Metabolic Diseases Advisory Committee voted favorably that the data support arimoclomol as an effective treatment for Niemann-Pick disease type C, a rare and progressive neurodegenerative disorder. The committee's recommendation will be considered by the FDA as it completes its review of the arimoclomol new drug application.

ZVRA Niemann-Pick Disease Type C Arimoclomol FDA Advisory Committee Rare Disease

Sentiment note

The article reports that the FDA advisory committee voted favorably on the data supporting arimoclomol, Zevra's investigational drug for Niemann-Pick disease type C, indicating the potential for the drug's approval and commercialization.

Unknown Jun 25, 2024 • 11:30 UTC GlobeNewswire Inc. • Zevra Therapeutics

Zevra Therapeutics Expands Executive Leadership Team

Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer

ZVRA Directors and Officers

Unknown Jun 18, 2024 • 11:30 UTC GlobeNewswire Inc. • Zevra Therapeutics

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Visit OLPRUVA-Prescribing-Information.pdf (olpruva.com) to view the full Prescribing Information, including Important Safety Information.

ZVRA Partnerships

Unknown Jun 3, 2024 • 15:00 UTC GlobeNewswire Inc. • Zevra Therapeutics

Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog

ZVRA Calendar of Events Clinical Study

Unknown May 8, 2024 • 12:15 UTC Zacks Investment Research • Zacks Equity Research

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ZVRA ALPN

Unknown May 7, 2024 • 11:15 UTC Zacks Investment Research • Zacks Equity Research

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ESPR ZVRA

Unknown May 2, 2024 • 14:01 UTC Zacks Investment Research • Zacks Equity Research

Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPTN ZVRA